Cover Image
市場調查報告書

牙齦炎:開發平台分析

Gingivitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200452
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
牙齦炎:開發平台分析 Gingivitis - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 33 Pages
簡介

牙齦炎是細菌感染造成的牙齦發炎。症狀有知覺過敏、牙齒和齒齦間發膿、掉牙、牙齦紅腫等。風險要素有糖尿病、抽煙、嚼煙、充填物損壞、缺乏免疫力、遺傳等要素。治療則使用抗生素。

本報告提供牙齦炎的治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,以及最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

牙齦炎概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • TGV-Laboratories
  • VivaCell Biotechnology Espana S.L

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8698IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gingivitis - Pipeline Review, H2 2016, provides an overview of the Gingivitis (Mouth And Dental Disorders) pipeline landscape.

Gingivitis is an inflammation of the gums, usually caused by a bacterial infection. Symptoms include sensitive teeth, pus between teeth and gums, loose teeth, gums that are red, tender, or swollen. Risk factors include diabetes, smoking or chewing tobacco, broken fillings, compromised immunity, and genetic factors. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gingivitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gingivitis (Mouth And Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gingivitis (Mouth And Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gingivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Unknown stages are 1, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 2 molecules, respectively.Gingivitis.

Gingivitis (Mouth And Dental Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gingivitis (Mouth And Dental Disorders).
  • The pipeline guide reviews pipeline therapeutics for Gingivitis (Mouth And Dental Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gingivitis (Mouth And Dental Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gingivitis (Mouth And Dental Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gingivitis (Mouth And Dental Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gingivitis (Mouth And Dental Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gingivitis (Mouth And Dental Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Gingivitis Overview 6
  • Therapeutics Development 7
  • Pipeline Products for Gingivitis - Overview 7
  • Pipeline Products for Gingivitis - Comparative Analysis 8
  • Gingivitis - Therapeutics under Development by Companies 9
  • Gingivitis - Therapeutics under Investigation by Universities/Institutes 10
  • Gingivitis - Pipeline Products Glance 11
  • Clinical Stage Products 11
  • Unknown Stage Products 12
  • Gingivitis - Products under Development by Companies 13
  • Gingivitis - Products under Investigation by Universities/Institutes 14
  • Gingivitis - Companies Involved in Therapeutics Development 15
  • General Biologicals Corp 15
  • TGV-Laboratories 16
  • Gingivitis - Therapeutics Assessment 17
  • Assessment by Monotherapy Products 17
  • Assessment by Target 18
  • Assessment by Mechanism of Action 19
  • Assessment by Route of Administration 20
  • Assessment by Molecule Type 22
  • Drug Profiles 24
  • BLXA-4ME - Drug Profile 24
  • Product Description 24
  • Mechanism Of Action 24
  • R&D Progress 24
  • KSL-W - Drug Profile 25
  • Product Description 25
  • Mechanism Of Action 25
  • R&D Progress 25
  • Mul-1867 - Drug Profile 26
  • Product Description 26
  • Mechanism Of Action 26
  • R&D Progress 26
  • PAC-113 - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • ST-266 - Drug Profile 29
  • Product Description 29
  • Mechanism Of Action 29
  • R&D Progress 29
  • Gingivitis - Dormant Projects 31
  • Appendix 32
  • Methodology 32
  • Coverage 32
  • Secondary Research 32
  • Primary Research 32
  • Expert Panel Validation 32
  • Contact Us 32
  • Disclaimer 33

List of Tables

  • Number of Products under Development for Gingivitis, H2 2016 7
  • Number of Products under Development for Gingivitis - Comparative Analysis, H2 2016 8
  • Number of Products under Development by Companies, H2 2016 9
  • Number of Products under Investigation by Universities/Institutes, H2 2016 10
  • Comparative Analysis by Clinical Stage Development, H2 2016 11
  • Comparative Analysis by Unknown Stage Development, H2 2016 12
  • Products under Development by Companies, H2 2016 13
  • Products under Investigation by Universities/Institutes, H2 2016 14
  • Gingivitis - Pipeline by General Biologicals Corp, H2 2016 15
  • Gingivitis - Pipeline by TGV-Laboratories, H2 2016 16
  • Assessment by Monotherapy Products, H2 2016 17
  • Number of Products by Stage and Target, H2 2016 18
  • Number of Products by Stage and Mechanism of Action, H2 2016 19
  • Number of Products by Stage and Route of Administration, H2 2016 21
  • Number of Products by Stage and Molecule Type, H2 2016 23
  • Gingivitis - Dormant Projects, H2 2016 31

List of Figures

  • Number of Products under Development for Gingivitis, H2 2016 7
  • Number of Products under Development for Gingivitis - Comparative Analysis, H2 2016 8
  • Number of Products under Development by Companies, H2 2016 9
  • Comparative Analysis by Clinical Stage Development, H2 2016 11
  • Assessment by Monotherapy Products, H2 2016 17
  • Number of Products by Routes of Administration, H2 2016 20
  • Number of Products by Stage and Routes of Administration, H2 2016 20
  • Number of Products by Molecule Types, H2 2016 22
  • Number of Products by Stage and Molecule Types, H2 2016 22
Back to Top